Does the PBS Cover Weight Loss Medicines? The Australian Answer

The short version

• The PBS does subsidise semaglutide for type 2 diabetes, under the Ozempic brand, with authority restrictions.
• The PBS does not subsidise any medicine for weight management on its own, as at July 2026.
• Mounjaro has never been PBS listed for anything. The PBAC said no twice for type 2 diabetes, in July 2023 and November 2024.
• Wegovy was recommended in November 2025 for a narrow group: adults with established cardiovascular disease and obesity. That listing had not gone live when we last checked.
• Until it does, weight management medicines in Australia are a private script at the full price the pharmacy charges.

Two systems people keep merging into one

Almost every confused conversation about this comes down to treating two separate decisions as if they were one.

Whether a medicine may be sold here, and for what, is decided by the TGA. That is registration. It is a scientific assessment of quality, safety and whether the medicine does what the sponsor claims for a stated use. Mounjaro and Wegovy have both cleared it for weight management.

The PBAC decides whether taxpayers help pay for it. The Pharmaceutical Benefits Advisory Committee is an independent expert committee that advises the Minister on which medicines should be listed on the PBS. It weighs clinical effectiveness against cost effectiveness, at the price the sponsor is asking, across the whole population that would be eligible. A medicine can work well and still fail that test, usually because the asking price against the expected benefit does not stack up at national scale.

So "approved in Australia" and "subsidised in Australia" are different sentences. A pharmacist can lawfully dispense you Mounjaro tomorrow on a valid script. You will pay for all of it.

What the PBS does subsidise

Semaglutide is PBS listed for type 2 diabetes under the brand Ozempic. It sits on the General Schedule as an Authority Required listing, which means the prescriber has to meet the written criteria rather than simply deciding to prescribe it.

The restrictions are real and they trip people up. Broadly, PBS subsidised GLP-1 therapy for type 2 diabetes requires that you have been contraindicated to, intolerant of, or not responded adequately to an SGLT2 inhibitor first, and it is subsidised for use alongside at least one of metformin, a sulfonylurea or insulin. It is not a first-line subsidy and it is not available for having a high BMI.

This is why some Australians pay very little for semaglutide and others pay everything. It is not the same script, and it is not the same brand.

What it does not subsidise

As at July 2026, there is no PBS listing for a medicine whose purpose is weight management alone. Not Mounjaro, not Wegovy, not anything else in the class. If you are prescribed one for weight, it is a private script.

A few consequences follow that people do not always expect. A private script does not count towards the PBS Safety Net, because the Safety Net only counts PBS items. Nothing about being on a Health Care Card or a pensioner concession card changes the price of a private script either. And your out-of-pocket cost is whatever the pharmacy charges, which is a commercial decision that varies between pharmacies.

Every decision, in order

Here is the actual record from the PBS medicine status pages, rather than the version that circulates on social media. Each row links to its source in the Sources section below.

Read down that column and the pattern is clear enough. Four submissions, three refusals, and the one recommendation is for a cardiovascular population rather than for weight loss as such. Nobody has yet made the case to the PBAC, at a price it accepted, for subsidising these medicines for obesity generally.

Where the Wegovy listing has got to

A PBAC recommendation is a step, not a finish line. After it, the sponsor and the Department have to agree the subsidised price and the exact prescribing conditions, then government processes run, then the listing goes live and pharmacy software is updated. The PBS says this normally takes about five months from the point the sponsor lodges its documentation, and longer for complex or high-impact medicines.

The published trail for Wegovy runs like this:

• PBAC meeting held 5 November 2025, outcome recommended.
• Notice of intent submitted by the sponsor on 20 February 2026.
• Required documentation lodged on 27 February 2026.
• Acceptance of that documentation is recorded as not accepted, and the next three steps, agreement to listing arrangements, government processes and listing itself, are all recorded as not yet commenced.

Against "medicine listed on the PBS", the page says: has not yet occurred. That was the position on the medicine status page when we checked it on 25 July 2026, and it is the page to check rather than a news article, because news articles about intentions do not get updated when timelines slip.

One more thing worth setting expectations about. The eligibility wording is settled at listing, not at recommendation, so the criteria you may have read in coverage of the announcement are not final until the listing appears. If you have had a heart attack or a stroke and are living with obesity, this is a live conversation to have with your GP. If you are looking for weight loss without that history, this particular listing was never going to be the route.

The bigger review, and who the PBAC named

In March 2025 the Health Minister asked the PBAC for advice on equitable access to GLP-1 obesity treatments through the PBS, including which groups would benefit most and how long treatment should be subsidised for. The PBAC gave that advice at its November 2025 meeting and the outcome was published on 19 December 2025.

The PBAC said priority for any subsidised access should include people with established cardiovascular disease, Aboriginal and Torres Strait Islander patients with obesity-related comorbidities, people with syndromic obesity, people with medication-induced obesity, and patients who need to lose weight to be eligible for surgery. It invited sponsors to make submissions for those populations, and noted that any listing still has to clear the usual legislative tests for clinical and cost effectiveness.

It also advised a slow and managed roll-out, and said that while there may be merit in broader subsidy for early intervention and prevention, that would probably need to be built as a program outside the PBS rather than inside it.

Read plainly: the direction of travel is towards subsidised access for defined clinical groups, arriving in stages, over years rather than months. It is not a signal that a general weight loss listing is close.

What that means for you today

• If you have type 2 diabetes, ask your GP whether you meet the PBS authority criteria for a subsidised GLP-1. Plenty of people who qualify have never been told they do.
• If you have established cardiovascular disease and obesity, the Wegovy listing is the one to watch, and your GP is the person to watch it with.
• If you are seeking weight loss without either, this is a private script at full cost, and it is worth planning for that as an ongoing expense rather than a one-off, because appetite typically returns when the medicine stops.
• Whatever your situation, keeping a clear record of weight, food, doses and symptoms costs nothing and makes every one of those conversations shorter.

How to check the status yourself

You do not have to take our word for any of this, and you should not have to, because it will change. The PBS runs a Medicine Status website that shows exactly which step each submission has reached, updated as things move. Search the active ingredient rather than the brand, so semaglutide rather than Wegovy, because one ingredient can have several submissions running at once for different uses.

The pages we relied on are all in the Sources list below, with the dates we read them. If you are reading this months after it was written, check there first.

FAQs